Child Vision, Inc. enters into Letter of Intent with Shanghai Yutong Pharmaceuticals, Ltd.

New York (CHVI:OTC) On June 17, 2005 Child Vision Inc, a Delaware Corporation has entered into a Letter of Intent to acquire 100% of all outstanding and common shares of Shanghai Yutong Pharmaceuticals, Ltd. Pursuant to the Letter of Intent, Child Vision, Inc will issue 1,817,360 shares of authorized and unissued stock in exchange for 7,249,441 shares of issued and outstanding stock of Shanghai Yutong Pharmaceuticals, Ltd. The purchased shares will be delivered to the shareholders in a ratio of 4 shares of Shanghai Yutong Pharmaceuticals, Ltd for each one share of Child Vision, Inc. As previously state, the Board of Directors has also agreed to change the name from Child Vision, Inc. to Shanghai Yutong Pharmaceuticals, Inc within due course. About Shanghai Yutong Pharmaceuticals, Inc. The Company specializes in the development and commercialization of Chinese herbal medicines and biological pharmaceuticals. The Company operates from a 90,000 square foot GMP-approved facility and markets over 13 different types of Chinese Medicine. The Company's flagship product Qilisheng Oral Solution core technique has been granted a U.S. patent. Legal Disclaimer The statements contained in this press release contain certain forward looking statements, including statements regarding the company's expectations, intentions, strategies and beliefs regarding the future. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without the control of the company's management. For Further Information: Rick Oravec rick@vircomglobal.com 212-422-3601